Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Acorda Therapeutics Inc    ACOR   US00484M1062

 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/26/2015 01/27/2015 01/28/2015 01/29/2015 01/30/2015 Date
44.5(c) 43.7(c) 42.54(c) 42(c) 41.55(c) Last
527 225 412 729 495 018 802 096 714 518 Volume
+1.69% -1.80% -2.65% -1.27% -1.07% Change
More quotes
Company
Acorda Therapeutics, Inc. engages in the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the nervous system.The company's two main products are Ampyra and Zanaflex... 
Sector
Biotechnology & Medical Research
Calendar
02/10 | 02:30pmPresentation
More about the company
Surperformance© ratings of Acorda Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Chart ACORDA THERAPEUTICS INC
Duration : Period :
Acorda Therapeutics Inc Technical Analysis Chart | ACOR | US00484M1062 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 390 M
EBIT 2014 43,4 M
Net income 2014 20,5 M
Debt 2014 205 M
Yield 2014 -
Sales 2015 423 M
EBIT 2015 20,4 M
Net income 2015 3,00 M
Debt 2015 153 M
Yield 2015 -
PER 2014 87,16
PER 2015 242,84
EV / Sales 2014 4,99x
EV / Sales 2015 4,48x
Capitalization 1 743 M
More Financials
Latest news on ACORDA THERAPEUTICS INC
01/27 Investing in Westchester's biotech surge
01/12 ACORDA THERAPEUTICS : Results of Operations and Financial Condition, Financial S..
01/12 ACORDA THERAPEUTICS : Provides Corporate Update at J.P. Morgan Healthcare Confer..
01/08 ACORDA THERAPEUTICS : Researchers Submit Patent Application, "Methods for Detect..
01/07 ACORDA THERAPEUTICS : Investigators at Acorda Therapeutics Describe Findings in ..
01/06 ACORDA THERAPEUTICS : to Present at the 33rd Annual J.P. Morgan Healthcare Confe..
2014 ACORDA THERAPEUTICS : Commences Phase 3 Clinical Trial for Dalfampridine
2014 ACORDA THERAPEUTICS : Announces Initiation of Phase 3 Clinical Trial for Dalfamp..
More news
Sector news Bio Therapeutic Drugs
01/30 PHARMACYCLICS : Johnson & Johnson: U.S. FDA Approves IMBRUVICA (ibrutinib) for t..
01/29DJValeant to Buy Prostate-Cancer Drug From Dendreon
01/29DJValeant in Deal to Buy Prostate-Cancer Drug Provenge From Dendreon
Plus d'actualités du secteur Bio Therapeutic Drugs


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF